Methotrexate Monitoring (5.13.2022)

Save

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.

Can You Reduce Frequency of Methotrexate Monitoring?

Save

Observational research presented at the British Society for Rheumatology meeting suggest that, based on the COVID-19 pandemic experience, reduced frequency of routine lab monitoring in patients receiving weekly methotrexate therapy for rheumatoid arthritis (RA) was not associated with an increase in adverse outcomes.

Bimekizumab's Favorable Safety Profile in Psoriasis

Save

A 2-year safety study of bimekizumab, the dual IL-17A/F inhibitor, plaque psoriasis patients showed bimekizumab (BMK), to be effective, well tolerated, with no new safety concerns other than a modest risk of oral candidiasis.

RNL 2022: Psoriatic Arthritis Advances

Save

Tuesday Nite Rheumatology on 10 May 2022 featured session highlights from RheumNow Live 2022.

This webinar presented exerpts from these lectures along with audience Q & A

ASCORE: Seropositivity Favors Abatacept Drug Survival

Save

The ASCORE (Abatacept SubCutaneOus in Routine clinical practicE) study evaluated efficacy, safety, and drug retention (durability) of abatacept (ABA) moderate-to-severe rheumatoid arthritis (RA) and found consistently better ABA durability in those who were seropositive. 

What is JAKne? (5.6.2022)

Save

Dr. Jack Cush reviews the news, journal reports, FDA actions, new side effects and changing prevalence of Gout.

Lack of Research Stymies Uptake of Medical Marijuana for Rheumatic Pain

Save

A new review article from CreakyJoints finds that there has been limited progress in understanding the potential of cannabis based therapies for the treatment of pain associated with rheumatic conditions in the past five years because of a lack of standardization of clinical research and barriers to conducting research due to existing federal and state regulations.

Acne with JAK Inhibitors

Save

JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAK inhibitors (JAKi).

BSR Guideline on Idiopathic Inflammatory Myopathy

Save

The British Society of Rheumatology (BSR) has published evidence-based guidelines for idiopathic inflammatory myopathy (IIM) affecting juvenile and adult-onset disease. This rare condition has an estimated prevalence of 5-15 per 100,000 persons.

Allopurinol Use Does Not Increase Mortality in Gout with Chronic Kidney Disease

Save

A population based trial has shown that allopurinol use dose escalation and achieving target uric acid levels (with allopurinol), was not associated with increased mortality in patients with gout and concurrent CKD

Trends in Rheumatoid Arthritis Disabililty, Despite Biologics

Save

Disability claims in the U.S. related to rheumatoid arthritis (RA) were just as common in 2015 as in 1999, a government researcher found, against expectations that the advent of biologic therapy would have led to a steady decrease.

Upadacitinib FDA Approved for Ankylosing Spondylitis

Save

Abbvie has announced the US Food and Drug Administration has approved upadacitinib (Rinvoq or UPA) for use in adults with active ankylosing spondylitis, who have not responded or been intolerant of one or more TNF blockers. The recommended dose is 15 mg per day.